Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow Quality Index
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow Quality Index of 4.56x as of December 2025. Operating cash flow of CN¥552.13 Million exceeds net income of CN¥121.03 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Tasly Pharmaceutical Group Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Tasly Pharmaceutical Group Co Ltd Cash Flow Quality Index (2001–2025)
Historical Cash Flow Quality Index for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check total reinvestment intensity of Tasly Pharmaceutical Group Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year earnings quality comparison for Tasly Pharmaceutical Group Co Ltd. For live market cap and the full company financial profile, see Tasly Pharmaceutical Group Co Ltd (600535) market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.29x | CN¥1.42 Billion | CN¥1.11 Billion | ▼ -45.0% |
| 2024 | 2.35x | CN¥2.01 Billion | CN¥859.06 Million | ▼ -7.4% |
| 2023 | 2.53x | CN¥2.58 Billion | CN¥1.02 Billion | ▼ -91.4% |
| 2022 | 29.31x | CN¥2.29 Billion | CN¥77.97 Million | ▲ +2419.1% |
| 2021 | 1.16x | CN¥2.80 Billion | CN¥2.41 Billion | ▼ -26.9% |
| 2020 | 1.59x | CN¥1.79 Billion | CN¥1.13 Billion | ▼ -5.0% |
| 2019 | 1.67x | CN¥1.68 Billion | CN¥1.00 Billion | ▲ +78.5% |
| 2018 | 0.94x | CN¥1.49 Billion | CN¥1.59 Billion | ▲ +260.0% |
| 2017 | -0.59x | CN¥-822.56 Million | CN¥1.40 Billion | ▼ -162.0% |
| 2016 | 0.95x | CN¥1.15 Billion | CN¥1.22 Billion | ▲ +324.1% |
| 2015 | 0.22x | CN¥340.00 Million | CN¥1.52 Billion | ▼ -47.5% |
| 2014 | 0.43x | CN¥616.76 Million | CN¥1.45 Billion | ▲ +43.3% |
| 2013 | 0.30x | CN¥346.17 Million | CN¥1.17 Billion | ▼ -43.1% |
| 2012 | 0.52x | CN¥413.31 Million | CN¥792.08 Million | ▲ +147.1% |
| 2011 | 0.21x | CN¥135.14 Million | CN¥639.96 Million | ▼ -75.4% |
| 2010 | 0.86x | CN¥395.05 Million | CN¥459.43 Million | ▼ -30.5% |
| 2009 | 1.24x | CN¥400.39 Million | CN¥323.63 Million | ▲ +19.0% |
| 2008 | 1.04x | CN¥260.21 Million | CN¥250.38 Million | ▼ -23.6% |
| 2007 | 1.36x | CN¥221.55 Million | CN¥162.97 Million | ▲ +106.7% |
| 2006 | 0.66x | CN¥140.56 Million | CN¥213.70 Million | ▼ -40.4% |
| 2005 | 1.10x | CN¥214.90 Million | CN¥194.60 Million | ▼ -5.1% |
| 2004 | 1.16x | CN¥203.27 Million | CN¥174.63 Million | ▲ +180.6% |
| 2003 | 0.41x | CN¥59.00 Million | CN¥142.22 Million | ▼ -76.4% |
| 2002 | 1.76x | CN¥206.22 Million | CN¥117.27 Million | ▲ +116.8% |
| 2001 | 0.81x | CN¥83.77 Million | CN¥103.29 Million | — |